


5 What is Claimed:

1. A compound of Formula (I):




wherein:

- 10 Z¹ and Z² are independently -NR³- (wherein R³ is hydrogen or alkyl) or -O-;
R¹ and R² are independently substituted alkyl, substituted aryl, heteroaryl, or
substituted heteroaryl provided that at least one of R¹ and R² is a group that can form a
pharmaceutically acceptable acid addition salt;
R³ is hydrogen, alkyl or R³ and R¹ or R² together with the atoms to which they are
15 attached form a heterocyclic ring;
X² is aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkenyl, alkynyl,
cycloalkyl or heterocyclic;
X¹ and X³ are independently aryl, substituted aryl, heteroaryl, substituted heteroaryl,
or -CHR⁴, wherein R⁴ is natural or unnatural amino acid side chain;
20 or a pharmaceutically acceptable acid addition salt thereof.

2. The compound of Claim 1, wherein Z¹ and Z² are -NH-.

3. The compound of Claim 2, wherein X² is aryl, substituted aryl, heteroaryl or
25 substituted heteroaryl.



















4. The compound of Claim 2, wherein R¹ and R² are independently substituted
alkyl groups.

- 
5. The compound of Claim 3, wherein X² is an aryl, substituted aryl, heteroaryl
or substituted heteroaryl moiety selected from a group consisting of the following moieties:

Indole









000000-000000

10






10340-666660

5



10



15

wherein,

R⁵ is hydrogen, alkyl or substituted alkyl;

R⁶ is hydrogen, alkyl, halo or alkoxy;

R⁷ is hydrogen, alkyl or halo;

R⁸ is hydrogen, alkyl, substituted alkyl, alkoxy or halo;

R⁹ is hydrogen, alkyl, substituted alkyl, alkoxy, nitro or halo;

R¹⁰ is hydrogen or alkyl;


R¹¹ is hydrogen or alkyl; and,

R¹² is hydrogen or alkyl.

20

5

6. The compound of Claim 2, wherein X^1 and X^3 are heteroaryl or substituted heteroaryl moieties independently selected from a group consisting of the following moieties:





wherein

R^{13} is hydrogen or alkyl; and,

R^{14} is hydrogen, alkyl or substituted alkyl.

7. The compound of Claim 4, wherein R^1 and R^2 are substituted alkyl moieties independently selected from a group consisting of the following moieties:



5

wherein

R^{15} is hydrogen, hydroxyl, alkoxy, alkyl, cycloalkyl or R^{15} and R^{16} together with the atoms to which they are attached form a heterocyclic ring;

R^{16} is hydrogen, hydroxyl, alkyl or cycloalkyl;

10

R^{17} , R^{18} , R^{19} and R^{20} are independently hydrogen or alkyl;

R^{21} is hydrogen alkyl, substituted alkyl, cycloalkyl or acyl;

R^{22} is hydrogen or alkyl, or R^{22} and R^{23} together with the atoms to which they are attached form a heterocyclic ring, or R^{22} and R^{24} together with the atoms to which they are attached form a heterocyclic ring.

15

R^{23} is hydrogen, hydroxyl, alkyl, cycloalkyl or R^{23} and R^{24} together with the atoms to which they are attached form a heterocyclic ring;

R^{24} is hydrogen, hydroxyl or alkyl;


m is 1, 2 or 3;

n is 1, 2 or 3; and,


20

o is 0, 1, 2 or 3.

8. The compound of Claim 6, wherein R^{14} is an alkyl or substituted alkyl moiety, and wherein the moiety is selected from a group consisting of the following moieties:




25



5

9. The compound of Claim 5, wherein X^1 and X^3 are heteroaryl or substituted heteroaryl moieties independently selected from a group consisting of the following moieties:




15 wherein

R^{13} is hydrogen or alkyl;

R^{14} is hydrogen, alkyl or substituted alkyl;

- 5 and wherein R^1 and R^2 are substituted alkyl moieties independently selected from a group consisting of the following moieties:



wherein

- 10 R^{15} is hydrogen, hydroxyl, alkoxy, alkyl, cycloalkyl or R^{15} and R^{16} together with the atoms to which they are attached form a heterocyclic ring;

R^{16} is hydrogen, hydroxyl, alkyl or cycloalkyl;

R^{17} , R^{18} , R^{19} and R^{20} are independently hydrogen or alkyl;

R^{21} is hydrogen alkyl, substituted alkyl, cycloalkyl or acyl;

- 15 R^{22} is hydrogen or alkyl, or R^{22} and R^{23} together with the atoms to which they are attached form a heterocyclic ring, or R^{22} and R^{24} together with the atoms to which they are attached form a heterocyclic ring.

R^{23} is hydrogen, hydroxyl, alkyl, cycloalkyl or R^{23} and R^{24} together with the atoms to which they are attached form a heterocyclic ring;


- 20 R^{24} is hydrogen, hydroxyl or alkyl;

m is 1, 2 or 3;


n is 1, 2 or 3; and,

o is 0, 1, 2 or 3.

- 25 10. The compound of Claim 9, wherein X^2 is




11. The compound of Claim 9, wherein X^1 and X^3 are both



5


12. The compound of Claim 10, wherein R^1 and R^2 are of the following structure:



wherein

- R^{17} and R^{18} are hydrogen; and,
 R^{21} is hydrogen, alkyl or acyl.

13. The compound of Claim 11, wherein R^1 and R^2 are of the following structure:




wherein

- R^{15} and R^{16} are hydrogen; and,
 n is 1 or 2.




14. The compound of Claim 12, wherein R^{19} and R^{20} are hydrogen, and wherein R^{21} is an alkyl group selected from a group consisting of methyl, ethyl and propyl, or an acyl moiety of the structure $-C(O)C(R^{25})(R^{26})H$,

wherein



- R^{25} is a substituent selected from a group consisting of the following substituents:




5



10




15



5

or R²⁵ and R²⁶ together with the atom to which they are attached form a heterocyclic ring of the following structure:



and wherein R²⁶ is a substituent selected from a group consisting of the following substituents: -H, -NH₂ and -NHCH₃.

15. The compound of Claim 12, wherein R¹ and R² are independently of one of the following structures:




wherein

R¹⁹ and R²⁰ are independently hydrogen or alkyl; and,


R²¹ is hydrogen, alkyl or acyl.

20


16. The compound of Claim 13, wherein R¹⁴ is an alkyl or substituted alkyl moiety, and wherein the moiety is selected from a group consisting of the following moieties:



5



17. The compound according to Claim 14, wherein the compound is of the following structure:



18. The compound according to Claim 16, wherein the compound is of the following structure:



10



15



Z¹ and Z² are independently -NR³- (wherein R³ is hydrogen or alkyl) or -O-;


5 R¹ and R² are independently substituted alkyl, substituted aryl, heteroaryl, or substituted heteroaryl provided that at least one of R¹ and R² is a group that can form a pharmaceutically acceptable acid addition salt;

R³ is hydrogen, alkyl or R³ and R¹ or R² together with the atoms to which they are attached form a heterocyclic ring;

10 X² is aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkenyl, alkynyl, cycloalkyl or heterocyclic;

X¹ and X³ are independently aryl, substituted aryl, heteroaryl, substituted heteroaryl, or -CHR⁴, wherein R⁴ is natural or unnatural amino acid side chain; or a pharmaceutically acceptable acid addition salt thereof.

15 20. A method of inhibiting topoisomerase, wherein the method comprises administration of a therapeutically effective amount of a compound of Formula (I):



(I)

wherein:

Z¹ and Z² are independently -NR³- (wherein R³ is hydrogen or alkyl) or -O-;


20 R¹ and R² are independently substituted alkyl, substituted aryl, heteroaryl, or substituted heteroaryl provided that at least one of R¹ and R² is a group that can form a pharmaceutically acceptable acid addition salt;

R³ is hydrogen, alkyl or R³ and R¹ or R² together with the atoms to which they are attached form a heterocyclic ring;

25 X² is aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkenyl, alkynyl, cycloalkyl or heterocyclic;


X¹ and X³ are independently aryl, substituted aryl, heteroaryl, substituted heteroaryl, or -CHR⁴, wherein R⁴ is natural or unnatural amino acid side chain; or a pharmaceutically acceptable acid addition salt thereof.

30 21. A method of treating bacterial infections, wherein the method comprises administration of a therapeutically effective amount of the following compound:





wherein R^{21} is hydrogen, alkyl, substituted alkyl, cycloalkyl or acyl.

22. A method of treating fungal infections, wherein the method comprises administration of a therapeutically effective amount of the following compound:



wherein R^{14} is hydrogen, $-\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$ or $-\text{CH}_2(\text{C}_3\text{H}_5)$, and wherein X^2 is a moiety selected from a group consisting of the following moieties:





5

wherein

R^5 is hydrogen, alkyl or substituted alkyl;

R^8 is hydrogen, alkyl, substituted alkyl, alkoxy or halo;

10 R^9 is hydrogen, alkyl, substituted alkyl, alkoxy, nitro or halo;

R^{10} is hydrogen or alkyl; and,

R^{11} is hydrogen or alkyl.

23. A method of treating a bacterial or fungal infection, wherein the bacterial or
 15 fungal strain is selected from a group consisting of the following strains: *c. albicans*, *a. fumigatus*, *b. cereus*, *h. influenzae* and *p. aeruginosa*.

09899337-069604